Literature DB >> 29427328

Depletion of keratin 8/18 modulates oncogenic potential by governing multiple signaling pathways.

Richa Tiwari1,2, Indrajit Sahu1,2,3, Bihari Lal Soni1,2, Gajanan J Sathe4, Pankaj Thapa1,2, Pavan Patel1, Shruti Sinha1, Chella Krishna Vadivel1, Shweta Patel1, Sayli Nitin Jamghare1, Swapnil Oak1, Rahul Thorat1, Harsha Gowda4, Milind M Vaidya1,2.   

Abstract

Keratin 8/18, the predominant keratin pair of simple epithelia, is often aberrantly expressed in various squamous cell carcinomas (SCCs) including skin SCC. Its aberrant expression is correlated with increased invasiveness and poor prognosis of the same, although the underlying mechanism is still unclear. A previous report from our laboratory has shown K8-mediated regulation of α6β4 integrin signaling and thereby tumorigenic potential of oral SCC-derived cells. Another study on transgenic mouse model has shown that during skin carcinogenesis, K8 favors conversion of papillomas toward malignancy. In order to understand the role of K8 and allied mechanism in skin SCC, K8 was stably knocked down in a skin epidermoid carcinoma-derived A431 cells. K8 downregulation significantly reduced the tumorigenic potential of these cells. In agreement with our phenotypic data, differential quantitative proteomics followed by IPA analysis showed altered expression of many proteins associated with biological functions including 'Cancer', 'Cellular movement', 'Cell death and survival', and 'Cellular morphology'. Some of these proteins were TMS1, MARCKSL1, RanBP1, 14-3-3γ, Rho-GDI2, etc. Furthermore, to our surprise, there was a significant reduction in K17 protein stability upon loss of K8, probably due to its caspase-mediated degradation. This was supported by altered TMS1-NF-κB signaling, leading to increased apoptotic sensitivity of A431 cells which in turn affected 'Cell death and survival'. Moreover, MARCKSL1-Paxillin1-Rac axis was found to be deregulated bestowing a possible mechanism behind altered 'Cellular movement' pathway. Altogether our study unravels a much broader regulatory role of K8, governing multiple signaling pathways and consequently regulating oncogenic potential of skin SCC-derived cells. DATABASE: Proteome Xchange Consortium via PRIDE database (dataset identifier PXD007206).
© 2018 Federation of European Biochemical Societies.

Entities:  

Keywords:  MARCKSL1; TMS1; cell death and survival; cellular movement; quantitative proteomics

Mesh:

Substances:

Year:  2018        PMID: 29427328     DOI: 10.1111/febs.14401

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  5 in total

1.  Activin A-mediated epithelial de-differentiation contributes to injury repair in an in vitro gastrointestinal reflux model.

Authors:  Cedric Roudebush; Alma Catala-Valentin; Thomas Andl; Gregoire F Le Bras; Claudia D Andl
Journal:  Cytokine       Date:  2019-07-29       Impact factor: 3.861

2.  Validation study of MARCKSL1 as a prognostic factor in lymph node-negative breast cancer patients.

Authors:  Nina Gran Egeland; Marie Austdal; Bianca van Diermen-Hidle; Emma Rewcastle; Einar G Gudlaugsson; Jan P A Baak; Ivar Skaland; Emiel A M Janssen; Kristin Jonsdottir
Journal:  PLoS One       Date:  2019-03-11       Impact factor: 3.240

3.  High KRT8 Expression Independently Predicts Poor Prognosis for Lung Adenocarcinoma Patients.

Authors:  Longxiang Xie; Yifang Dang; Jinshuai Guo; Xiaoxiao Sun; Tiantian Xie; Lu Zhang; Zhongyi Yan; Hamel Amin; Xiangqian Guo
Journal:  Genes (Basel)       Date:  2019-01-10       Impact factor: 4.096

Review 4.  Intermediate Filaments as Effectors of Cancer Development and Metastasis: A Focus on Keratins, Vimentin, and Nestin.

Authors:  Pooja Sharma; Sarah Alsharif; Arwa Fallatah; Byung Min Chung
Journal:  Cells       Date:  2019-05-23       Impact factor: 6.600

5.  Transcript levels of keratin 1/5/6/14/15/16/17 as potential prognostic indicators in melanoma patients.

Authors:  Wei Han; Chan Hu; Zhao-Jun Fan; Guo-Liang Shen
Journal:  Sci Rep       Date:  2021-01-13       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.